Brief: Amgen Says Tezspire Safety Profile Consistent With Approved Indications
27/08/2026 07:31
BRIEF-Amgen Says Tezspire Safety Profile Consistent With Approved Indications Aug 27 (Reuters) - Amgen Inc AMGN.O:
TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS
AMGEN - TEZSPIRE SAFETY PROFILE CONSISTENT WITH APPROVED INDICATIONS
Source text: ID:nPnPR3nda
Further company coverage: AMGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amgen
See all newsUS RESEARCH ROUNDUP-Apple, Kaiser Aluminum, Reliance
Brief: Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer
Corrected: Amgen drug combined with immunotherapy extends survival in lung cancer trial
US RESEARCH ROUNDUP- Amgen, Lockheed Martin, Norfolk Southern
Eli Lilly hits record high as healthcare stocks rally